SHAREHOLDERS' EQUITY (Details) (USD $) In Millions, except Share data, unless otherwise specified	0 Months Ended	3 Months Ended		6 Months Ended
	Jun. 24, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 Common Shares	Jun. 30, 2013 Common Shares	Jun. 30, 2014 Additional Paid-In Capital	Jun. 30, 2013 Additional Paid-In Capital	Jun. 30, 2014 Accumulated Deficit	Jun. 30, 2013 Accumulated Deficit	Jun. 30, 2014 Accumulated Other Comprehensive Loss	Jun. 30, 2013 Accumulated Other Comprehensive Loss	Jun. 30, 2014 Valeant Pharmaceuticals International, Inc. Shareholders’ Equity	Jun. 30, 2013 Valeant Pharmaceuticals International, Inc. Shareholders’ Equity	Jun. 30, 2014 Noncontrolling Interest	Jun. 30, 2013 Noncontrolling Interest	Dec. 31, 2012 Noncontrolling Interest
Increase (Decrease) in Shareholders' Equity
Beginning Balance (in shares)				333,036,637		333,000,000	303,900,000
Beginning Balance				$ 5,233.3	$ 3,717.4	$ 8,301.2	$ 5,940.7	$ 228.8	$ 267.1	$ (3,278.5)	$ (2,371.0)	$ (132.8)	$ (119.4)	$ 5,118.7	$ 3,717.4	$ 114.6	$ 0	$ 0
Issuance of common stock (in shares)	27,058,824						27,100,000
Issuance of common stock	2,300.0				2,269.5		2,269.5								2,269.5
Common shares issued under share-based compensation plans (in shares)						800,000	2,200,000
Common shares issued under share-based compensation plans				7.2	1.0	24.7	54.2	(17.5)	(53.2)					7.2	1.0
Repurchase of common shares (in shares)							(700,000)
Repurchase of common shares					(55.6)		(14.2)				(41.4)				(55.6)
Settlement of stock options				(3.1)				(3.1)						(3.1)
Share-based compensation				40.4	16.5			40.4	16.5					40.4	16.5
Employee withholding taxes related to share-based awards				(36.5)	(21.5)			(36.5)	(21.5)					(36.5)	(21.5)
Tax benefits from stock options exercised				1.2	16.4			1.2	16.4					1.2	16.4
Acquisition of noncontrolling interest				(3.3)				(1.1)						(1.1)		(2.2)
Total before comprehensive income (loss) (in shares)						333,800,000	332,500,000
Total before comprehensive income (loss)		5,239.2	5,943.7	5,239.2	5,943.7	8,325.9	8,250.2	212.2	225.3	(3,278.5)	(2,412.4)	(132.8)	(119.4)	5,126.8	5,943.7	112.4
Comprehensive income:
Net income (loss)		122.0	10.8	101.7	(16.7)					103.2	(16.7)			103.2	(16.7)	(1.5)
Other comprehensive income (loss)				26.4	(224.5)							28.1	(224.5)	28.1	(224.5)	(1.7)
Comprehensive income (loss)		156.4	(136.3)	128.1	(241.2)									131.3	(241.2)	(3.2)
Beginning Balance (in shares)		333,777,181		333,777,181		333,800,000	332,500,000
Ending Balance		$ 5,367.3	$ 5,702.5	$ 5,367.3	$ 5,702.5	$ 8,325.9	$ 8,250.2	$ 212.2	$ 225.3	$ (3,175.3)	$ (2,429.1)	$ (104.7)	$ (343.9)	$ 5,258.1	$ 5,702.5	$ 109.2	$ 0	$ 0